Sciety flags revived US biotech IPO market as 20 listings raise $6.1 billion in 2026
XBI•XBI•XBI•XBI•Sciety flagged a rebound in US biotech investor appetite, with 20 drug-development IPOs raising about $6.1 billion through mid-August 2026. Six summer Nasdaq biopharma IPOs raised $1.6 billion, while XBI was up more than 80% year-on-year by late August.
Sciety flagged stronger US biotech IPO issuance and broad sector gains. Through mid-August 2026, 20 US drug-development biotech IPOs raised about $6.1 billion, and six Nasdaq biopharma IPOs over the summer were upsized, raising $1.6 billion.
Parabilis Medicines raised $670 million, described as the largest biotech IPO on record. Most 2026 IPO issuers were late-stage, with 15 companies at or near Phase 2 or later; XBI was up more than 80% year-on-year by late August.
Sciety said Europe and the Nordics could see a pickup in biotech demand in the first half of 2027 if the prior cycle’s lag repeats.
